

April 16, 2009



Neurology Snapshot: Multiple Sclerosis

Event: American Academy of Neurology, April 25-May 2, 2009



MS Market Leaders

Roche / Biogen Idec (OTC:RHHBY / NASDAQ:BIIB): Rituxan (IV administration): *Peak sales estimate USD 8.324b*

[Genentech's Rituxan to see continued off-label use in MS, ocrelizumab positioned to be future anti-CD20, physicians say \(Pharmawire\)](#)

[Genentech's ocrelizumab for multiple sclerosis generates excitement but PML concerns still surround the anti-CD20 monoclonal antibody class, physicians say \(Pharmawire\)](#)

Teva (NASDAQ:TEVA): Copaxone (SC administration): *Peak sales estimate USD 3.230b*

[Teva's lawsuit against Sandoz/Momenta over Copaxone may be influenced by recent Indian Patent Office decision; Teva also faces other hurdles - attorneys \(Pharmawire\)](#)

[Momenta's ANDAs for generic Lovex, Copaxone likely delayed due to political uncertainty - analysis \(Pharmawire\)](#)

[Momenta mum on generic Copaxone trials; approval could be delayed past 30-month-stay, attorneys say \(Pharmawire\)](#)

Biogen Idec (NASDAQ:BIIB): Avonex (IV administration): *Peak sales estimate USD 2.740b*

[Biogen moves long acting version of Avonex into trials to get regulatory approval - report \(Boston Herald\)](#)

[Biogen Idec raises wholesale price of Avonex - report \(Boston Globe\)](#)

EMD Serono/Pfizer (DAX:MRK / NYSE:PFE): Rebif (SC administration): *Peak sales estimate USD 2.235b*

[Merck KGaA: results from IMPROVE study show therapeutic effect of new formulation of Rebif at 16 Weeks in patients with Multiple Sclerosis \(Company Press Release\(s\)\)](#)

[Genzyme's alemtuzumab is more efficacious than Pfizer's Rebif in the treatment of multiple sclerosis, physicians say \(Pharmawire\)](#)

Biogen Idec/Elan (NASDAQ:BIIB / NYSE:ELN): Tysabri (IV administration): *Peak sales estimate USD 1.602b*

[Biogen Idec's Tysabri will not see major drop off in patient population due to recent PML infection, but expansion looks less likely in MS - analysis \(Pharmawire\)](#)

[Elan's Tysabri PML risk still worries physicians, may affect other immunosuppressants like Enbrel, Humira, Remicade - analysis \(Pharmawire\)](#)



MS Candidates in Development

EMD Serono (DAX:MRK): cladribine (oral administration): Phase III

[Merck-Serono's chances with oral MS drug cladribine face physician scrutiny over single trial design \(Pharmawire\)](#)

[Merck Serono's MS drug cladribine sees physician concern regarding toxicity profile despite strong Phase III results \(Pharmawire\)](#)

Novartis (NYSE:NVS): FTY720 (oral administration): Phase III: *Peak sales estimate USD 925m*

[Novartis' oral MS drug FTY720 comes under physician scrutiny; side-effects affecting patient enrollment in US trial - analysis \(Pharmawire\)](#)

[Novartis's FTY720 shows low relapse rate for multiple sclerosis, but being monitored for potential risk of skin cancer, investigators say \(Pharmawire\)](#)

Biogen Idec (NASDAQ:BIIB): BG-12 (oral administration): Phase III

[Biogen Idec, Novartis: Patients likely to request oral MS drugs, once available; safety main hurdle, physicians say \(Pharmawire\)](#)

[Biogen's BG-12 for multiple sclerosis shows promise in potential combination therapy, but GI tolerability may be an issue, neurologists say \(Pharmawire\)](#)

Acorda Therapeutics (NASDAQ:ACOR): Fampridine - SR (oral administration): *Peak sales estimate USD 448m*

[Acorda to double current US sales force to prepare for Fampridine-SR launch, still seeks ex-US partner, CEO says; physicians like drug \(Pharmawire\)](#)

[Acorda Therapeutics said to be in 'very early' discussions with Biogen Idec \(Pharmawire\)](#)

BioMS (TSE:MS): Dirucotide (IV administration): Phase III

[BioMS faces binary event in 2Q09 on Eli Lilly opt-in decision on dirucotide, CEO says \(Pharmawire\)](#)

[BioMS: Dirucotide \(MBP8298\) for multiple sclerosis, long-term application possibility and low toxicity profile exciting, neurologists say \(Pharmawire\)](#)

Genzyme/Bayer (NASDAQ:GENZ / OTC:BAYRY): Campath (IV administration): Phase III

[Genzyme's Campath unlikely to be first-line treatment in multiple sclerosis, could play more of a rescue therapy role, physicians say \(Pharmawire\)](#)

[Genzyme's Campath potential for additional adverse events may limit use of drug in MS, physicians say \(Pharmawire\)](#)